LNTH Stock - Lantheus Holdings, Inc.
Unlock GoAI Insights for LNTH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.53B | $1.30B | $935.06M | $425.21M | $339.41M |
| Gross Profit | $988.29M | $709.54M | $581.70M | $187.69M | $138.76M |
| Gross Margin | 64.4% | 54.7% | 62.2% | 44.1% | 40.9% |
| Operating Income | $456.98M | $364.64M | $36.20M | $-60,825,000 | $-4,198,000 |
| Net Income | $312.44M | $326.66M | $28.07M | $-71,279,000 | $-13,473,000 |
| Net Margin | 20.4% | 25.2% | 3.0% | -16.8% | -4.0% |
| EPS | $4.52 | $4.79 | $0.41 | $-1.06 | $-0.25 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | Truist | Upgrade | Buy | $80 |
| October 8th 2025 | Goldman | Downgrade | Neutral | $77 |
| August 12th 2025 | Truist | Downgrade | Hold | $63 |
| December 18th 2024 | Goldman | Initiation | Buy | $143 |
| September 3rd 2024 | Redburn Atlantic | Initiation | Buy | $175 |
| July 10th 2024 | JMP Securities | Reiterated | Mkt Outperform | $130← $100 |
| December 18th 2023 | William Blair | Downgrade | Market Perform | - |
| December 4th 2023 | TD Cowen | Initiation | Outperform | $100 |
| September 29th 2023 | William Blair | Initiation | Outperform | - |
| March 8th 2023 | JMP Securities | Initiation | Mkt Outperform | $120 |
| November 30th 2022 | SVB Leerink | Initiation | Outperform | - |
| October 13th 2022 | Mizuho | Initiation | Buy | $105 |
| May 9th 2022 | B. Riley Securities | Initiation | Buy | $91 |
| April 13th 2022 | Truist | Initiation | Buy | $77 |
Earnings History & Surprises
LNTHEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $1.20 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.27 | $1.27 | 0.0% | = MET |
Q3 2025 | Aug 6, 2025 | $1.64 | $1.57 | -4.3% | ✗ MISS |
Q2 2025 | May 7, 2025 | $1.68 | $1.53 | -8.9% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $1.58 | $1.59 | +0.6% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $1.56 | $1.70 | +9.0% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $1.83 | $1.80 | -1.6% | ✗ MISS |
Q2 2024 | May 2, 2024 | $1.54 | $1.69 | +9.7% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $1.45 | $1.75 | +20.7% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $1.32 | $1.47 | +11.4% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $1.31 | $1.54 | +17.6% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $1.29 | $1.47 | +14.0% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $0.96 | $1.37 | +42.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.83 | $0.99 | +19.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.70 | $0.89 | +27.1% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $0.46 | $0.97 | +110.9% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $0.17 | $0.25 | +47.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.06 | $0.08 | +33.3% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.05 | $0.11 | +120.0% | ✓ BEAT |
Latest News
Truist Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $82
📈 PositiveMizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $72
📈 PositiveLantheus Holdings shares are trading higher after Truist Securities upgraded the stock from Hold to Buy and raised its price target from $61 to $80.
📈 PositiveTruist Securities Upgrades Lantheus Holdings to Buy, Raises Price Target to $80
📈 PositiveTruist Securities Reiterates Hold on Lantheus Holdings, Lowers Price Target to $61
➖ NeutralLNTH stock has given up its prior gain. Lantheus Holdings shares were trading higher after the company reported better-than-expected Q3 financial results.
➖ NeutralLantheus Holdings shares are trading higher after the company reported better-than-expected Q3 financial results. The company announced that CEO Brian Markinson will retire.
📈 PositiveLantheus Holdings Narrows FY2025 Adj EPS Guidance from $5.50-$5.70 to $5.50-$5.65 vs $5.63 Est; Raises FY2025 Sales Guidance from $1.475B-$1.510B to $1.490B-$1.510B vs $1.483B Est
📈 PositiveLantheus CEO Brian Markison To Retire, Effective Dec. 31; Mary Anne Heino Appointed Executive Chairperson, Interim CEO, Effective Nov. 7; President Paul Blanchfield Departing
📉 NegativeLantheus Holdings Q3 Adj. EPS $1.27 Beats $1.26 Estimate, Sales $384.014M Beat $363.365M Estimate
📈 PositiveLantheus Announces Mar. 29 PDUFA Date For LNTH-2501
➖ NeutralFDA Accepts Lantheus' NDA For MK-6240, Investigational F18-Labeled Tau-Targeted PET Imaging Agent For Detection Of Tau NFT Pathology In Patients With Alzheimer's Disease; PDUFA Date Set For August 13, 2026
📈 PositiveGoldman Sachs Downgrades Lantheus Holdings to Neutral, Lowers Price Target to $77
➖ NeutralB. Riley Securities Maintains Buy on Lantheus Holdings, Lowers Price Target to $84
➖ NeutralTD Cowen Maintains Buy on Lantheus Holdings, Lowers Price Target to $80
➖ NeutralLantheus announces FDA review for new radioactive imaging agent
📈 PositiveLantheus sinks 8% as CMS wants to maintain reimbursement model for radiopharmaceuticals
📉 NegativeLantheus Holdings stock drops on lowered full year outlook
📉 NegativeFrequently Asked Questions about LNTH
What is LNTH's current stock price?
What is the analyst price target for LNTH?
What sector is Lantheus Holdings, Inc. in?
What is LNTH's market cap?
Does LNTH pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LNTH for comparison